Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04772157 · ClinicalTrials.gov registry record
Safe Emergency Department DIscharGE Rate (SEIGE)
A clinical trial, sponsored by Hennepin Healthcare Research Institute.
- Completed
- Registry status
- 1,000
- Enrollment target
NCT04772157: Completed study, sponsored by Hennepin Healthcare Research Institute.
NCT04772157 is a clinical trial that has completed, run by Hennepin Healthcare Research Institute. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04772157 has completed, sponsored by Hennepin Healthcare Research Institute.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
The Siemens POC High Sensitivity Troponin-I Test System is an in vitro diagnostic test for the quantitative measurement of cardiac troponin I (cTn-I) in fresh human capillary (fingerstick) whole blood, and lithium-heparinized venous whole blood or plasma, to be used by healthcare professionals at the point of care (POC) as well as in the clinical laboratory. The Siemens POC High Sensitivity Troponin-I Test System is to be used as an aid in the diagnosis of myocardial infarction (MI).
Primary Outcome
Examine the incidence of undetectable(\<LoD), measurable (LoD - 99th percentile), and increased (\>99th percentile) cTn concentrations for the Siemens POC HS cTn-I Test System in comparison to a high sensitivity cTnI assay (Abbott \& Siemens Healthineers) to determine the potential impact on positivity rate, defined by sex-specific 99th percentiles.
Interventions
- DIAGNOSTIC_TEST Cardiac Troponin Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2024-10-13 |
What the finished NCT04772157 record still lists
NCT04772157 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Cardiac Troponin Testing is the first listed.
NCT04772157 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04772157 about?
NCT04772157 is a clinical study titled "Safe Emergency Department DIscharGE Rate (SEIGE)". The Siemens POC High Sensitivity Troponin-I Test System is an in vitro diagnostic test for the quantitative measurement of cardiac troponin I (cTn-I) in fresh human capillary (fingerstick) whole blood, and lithium-heparinized venous whole blood or plasma, to be used by healthcare professionals at th...
What is the current status of trial NCT04772157?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2020-10-13. Estimated completion is 2024-10-13.
What interventions are being tested in trial NCT04772157?
The interventions under investigation include: Cardiac Troponin Testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04772157?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI